Serina Therapeutics
Serina Therapeutics is a clinical-stage biotechnology company developing wholly-owned drug candidates to treat neurological diseases, pain, cancer, and metabolic disorders, using its POZ platform, a proprietary polyoxazoline polymer technology that enables controlled drug loading and release and attachment of small molecules, proteins, peptides, and DNA to modify pharmacokinetic profiles. The company’s pipeline includes SER-214 for Parkinson’s disease and restless legs syndrome, SER-226 for postoperative pain, SER-228 for refractory epilepsy, and SER-232 for chemotherapy-induced nausea and vomiting, among other POZ-based delivery programs. The POZ platform aims to improve safety and efficacy by achieving favorable pharmacokinetics compared with traditional polymers and broadens the range of compounds that can be effectively delivered. Serina Therapeutics was founded in 2006 and is based in Huntsville, Alabama.
Top Regions
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
1 past transactions
AgeX Therapeutics
Acquisition in 2024
AgeX Therapeutics, Inc. is a biotechnology company based in Alameda, California, specializing in the development and commercialization of innovative therapeutics aimed at addressing human aging and degenerative diseases. The company harnesses proprietary technologies, including telomerase-mediated cell immortality and induced Tissue Regeneration, to create novel treatments. Its product pipeline features two primary cell-based candidates: AGEX-BAT1, which targets age-related metabolic disorders such as Type II diabetes, and AGEX-VASC1, designed to restore vascular support in ischemic tissues. Additionally, AgeX is working on AGEX-iTR1547, a drug formulation intended to enhance regenerative potential in aged tissues suffering from degenerative conditions. The company also offers human embryonic stem cells and a suite of genomic interpretation tools for researchers. AgeX has collaborated with the University of California, Irvine, on neural stem cell research related to Huntington's disease and other neurological disorders. Founded in 2017, AgeX continues to advance its mission of addressing the challenges associated with aging.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.